Weekly Digest - June 2025

Weekly Digest - June 2025

03 June 2025: European Commission approves ADCETRIS (Brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV hodgkin lymphoma in combination with ECADD

  • Takeda’s ADCETRIS-based regimen BrECADD has been approved by the European Commission for the frontline treatment of adult patients with newly diagnosed Stage IIb (with risk factors), III, or IV Hodgkin lymphoma
  • The approval is based on the Phase 3 HD21 trial, which demonstrated BrECADD’s significantly superior safety profile and non-inferior progression-free survival compared to the standard eBEACOPP regimen  
  • ADCETRIS targets CD30, a hallmark of Hodgkin lymphoma, and this marks its second approved combination regimen for frontline treatment in the EU, expanding available therapeutic options

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home